CoChat

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Tripathy, Debu, Im, Seock-Ah, Colleoni, Marco, Franke, Fabio, Bardia, Aditya, Harbeck, Nadia, Hurvitz, Sara A, Chow, Louis, Sohn, Joohyuk, Lee, Keun Seok, Campos-Gomez, Saul, Villanueva Vazquez, Rafael, Jung, Kyung Hae, Babu, K Govind, Wheatley-Price, Paul, De Laurentiis, Michelino, Im, Young-Hyuck, Kuemmel, Sherko, El-Saghir, Nagi, Liu, Mei-Ching, Carlson, Gary, Hughes, Gareth, Diaz-Padilla, Ivan, Germa, Caroline, Hirawat, Samit, Lu, Yen-Shen · 2018 · The Lancet Oncology

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

BACKGROUND In MONALEESA-2, ribociclib plus letrozole showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer. MONALEESA-7 aimed to assess the efficacy and safety of ribociclib plus endocrine therapy in premenopausal women with advanced, HR-positive breast cancer. METHODS This phase 3, randomised, double-blind, placebo-controlled trial was done at 188 centres in 30 countries. Eligible patients were premenopausal women aged 18-59 years who had histologically or cytologically confirmed HR-positive, HER2-negative, advanced breast cancer; an Eastern Cooperative Oncology Group performance status of 0 or 1; measurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 criteria, or at least one predominantly lytic bone lesion; and had not received previous treatment with cyclin-dependent kinases 4 and 6 inhibitors. Endocrine therapy and chemotherapy in the adjuvant or neoadjuvant setting was permitted, as was up to one line of chemotherapy for advanced disease. Patients were randomly assigned (1:1) via interactive response technology to receive oral ribociclib (600 mg/day on a 3-weeks-on, 1-week-off schedule) or matching placebo with either oral tamoxifen (20 mg daily) or a non-steroidal aromatase inhibitor (letrozole 2·5 mg or anastrozole 1 mg, both oral, daily), all with goserelin (3·6 mg administered subcutaneously on d…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30292-4

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Cited by

See all 1,025

Metadata

Authors
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., Campos-Gomez, S., Villanueva Vazquez, R., Jung, K. H., Babu, K. G., Wheatley-Price, P., De Laurentiis, M., Im, Y.-H., Kuemmel, S., El-Saghir, N., Liu, M.-C., Carlson, G., Hughes, G., Diaz-Padilla, I., Germa, C., Hirawat, S., & Lu, Y.-S.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Seoul National University Hospital (KR)
  • European Institute of Oncology (IT)
  • Harvard University (US)
  • Ludwig-Maximilians-Universität München (DE)
  • University of California, Los Angeles (US)
  • Yonsei University Health System (KR)
  • National Cancer Center (KR)
  • Asan Medical Center (KR)
  • Samsung Medical Center (KR)
  • American University of Beirut Medical Center (LB)
  • Koo Foundation Sun Yat-Sen Cancer Center (TW)
  • Novartis (United States) (US)
  • Novartis (Switzerland) (CH)
  • National Taiwan University Hospital (TW)
Corresponding author
Lu, Yen-Shen
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2018-07
Volume
19
Issue
7
Pages
904-915
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2804105316
Cited by
1,025
References
36
Citations by year
2026: 90 · 2025: 134 · 2024: 137 · 2023: 141 · 2022: 124 · 2021: 152 · 2020: 124 · 2019: 89 · 2018: 31
FWCI
73.71
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
Novartis
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
ribociclib, CDK4/6 inhibitors, hormone receptor-positive breast cancer, HER2-negative breast cancer, premenopausal women, endocrine therapy, letrozole, tamoxifen, anastrozole, goserelin, progression-free survival, first-line therapy, advanced breast cancer, safety and tolerability
MeSH terms
Letrozole, Administration, Oral, Adult, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Humans, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Purines, Tamoxifen, Proportional Hazards Models, Survival Analysis, Treatment Outcome, Premenopause, Disease-Free Survival, Antineoplastic Agents, Hormonal, Internationality, Kaplan-Meier Estimate, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30292-4
The paper
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., Campos-Gomez, S., Villanueva Vazquez, R., Jung, K. H., Babu, K. G., Wheatley-Price, P., De Laurentiis, M., Im, Y.-H., Kuemmel, S., El-Saghir, N., . . . Lu, Y.-S. (2018). Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30292-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.